Sun Pharma’s victory reg launch of Leqselvi is a material positive. The Leqselvi opportunity is as significant as Ilumya is today by FY30....
Pharma stocks are down to expected tariff on generics. This is opportunity to buy Cos with diversified portfolios & lower reliance to US generics...
Sun Pharma's acquisition of Checkpoint Therapeutics gives it access to USFDA-approved novel drug asset, Cosibelimab, which has peak sales...
Separate names with a comma.
